Radioactive Iodine-Refractory Thyroid Cancer: Sorafenib, a New Treatment Option (video) European Society for Medical Oncology Share Print E-Mail Loading video... Caption L. Licitra shares her comments about randomized, phase III DECISION trial that studied sorafenib, an orally active inhibitor of VEGFR1-3 and Raf kinases, vs. placebo in patients with progressive locally advanced/metastatic radioactive iodine-refractory differentiated thyroid cancer. The standard treatment in this situation is a classical chemotherapy and now targeted therapy with sorafenib shows improved progression-free survival with tolerability consistent with known sorafenib safety profile. http://www.esmo.org Credit © European Society for Medical Oncology Usage Restrictions None Share Print E-Mail Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.